Abstract: The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc, at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.

Abstract: Provided are a GLP-1 (7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Abstract: The present disclosure relates to a polypeptide analog or a derivative thereof, and a preparation method and use thereof, and particularly to an agonistic polypeptide analog or a derivative thereof of an insulin amyloid polypeptide receptor. The polypeptide analog or the derivative thereof provided by the present disclosure has good agonistic activity on the insulin amyloid polypeptide receptor, has the characteristics of good stability, high activity, etc. at the same time, and can be used for treating and preventing diseases related to the insulin amyloid polypeptide receptor, such as body weight abnormality, especially obesity and overweight.

Abstract: Provided are a GLP-1 (7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Abstract: Disclosed in the present application is a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2?° of 7.83±0.2, 26.64±0.2 and 18.89±0.2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino] octanoate provided by the present application has four crystal forms, has high solubility and strong stability, can deliver drugs more effectively, increases the permeability of the delivered drugs in the gastrointestinal tract, and is beneficial to the preparation of oral preparations, such that preventive and/or therapeutic drugs can be better delivered into the body to achieve the effect of improving the bioavailability.

Abstract: Disclosed in the present application is a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2?° of 7.83±0.2, 26.64±0.2 and 18.89±0.2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate provided by the present application has four crystal forms, has high solubility and strong stability, can deliver drugs more effectively, increases the permeability of the delivered drugs in the gastrointestinal tract, and is beneficial to the preparation of oral preparations, such that preventive and/or therapeutic drugs can be better delivered into the body to achieve the effect of improving the bioavailability.

Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Abstract: Provided are an interleukin 29 (IL29) mutant protein, and a fusion protein, a conjugate, a pharmaceutical composition, a product and a kit which comprises the mutant protein. The provided IL29 mutant protein has good activity and stability, and can effectively prevent and/or treat viral infectious diseases, tumors and other diseases needing to regulate the body immune function.

Abstract: Disclosed in the present application is a crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate, wherein the crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate is crystal Form I, and the crystal Form I has at least an X-ray powder diffraction pattern with characteristic peaks represented by 2?° of 7.83±0.2, 26.64±0.2 and 18.89±0.2. The crystal polymorph of potassium N-[8-(2-hydroxybenzoyl)amino]octanoate provided by the present application has four crystal forms, has high solubility and strong stability, can deliver drugs more effectively, increases the permeability of the delivered drugs in the gastrointestinal tract, and is beneficial to the preparation of oral preparations, such that preventive and/or therapeutic drugs can be better delivered into the body to achieve the effect of improving the bioavailability.

Abstract: A method for displaying relevant information of an electrical red packet includes: acquiring a browsing operation of a user on a target page; determining, in response to the browsing operation, at least one associated account of an account of the user; searching for relevant information of an electrical red packet that the at least one associated account participated in before a triggering time point of the browsing operation; and displaying the relevant information on the target page.

Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Abstract: A method for displaying relevant information of an electrical red packet includes: acquiring a browsing operation of a user on a target page; determining, in response to the browsing operation, at least one associated account of an account of the user; searching for relevant information of an electrical red packet that the at least one associated account participated in before a triggering time point of the browsing operation; and displaying the relevant information on the target page.

Abstract: Provided are a GLP-1(7-37) polypeptide analogue, a fatty acid-modified derivative of the analogue, and a medicament comprising the derivative. Further, also provided are a preparation method of the derivative, and use of the same in the preparation of a medicament.

Abstract: The present invention relates to methods of purifying and analyzing preparations of Fc domain containing polypeptides comprising binding said polypeptide to protein A, more particularly to a protein A column, and eluting with a pH gradient elution system. This method enhances separation of aggregates, multimers and modified versions of the protein from the single Fc domain containing polypeptide.